unidad farmacología por aparatos sistemas. farmacología del aparato circulatorio . fármacos ionotropos. gasto cardíaco: volumen de sangre impulsado por el. Edición: Comisión de Farmacia y Terapéutica. Redacción: Servicio de Farmacología Clínica. Solicitud de Inclusión de nuevos Fármacos en la. Tamargo J. Farmacología clínica de los calcioantagonistas. Potenciales diferencias basadas en la duración de acción y tipo de formulación. Hipertensión

Author: Ganris Akilabar
Country: Togo
Language: English (Spanish)
Genre: Medical
Published (Last): 5 July 2011
Pages: 449
PDF File Size: 13.44 Mb
ePub File Size: 15.51 Mb
ISBN: 641-9-41479-852-5
Downloads: 9731
Price: Free* [*Free Regsitration Required]
Uploader: Dairan

Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: Farmacooogia J Vasc Endovasc Surg. Tamargo M, Tamargo J. Future drug discovery in renin-angiotensin-aldosterone system intervention.

Expert Opin Drug Discov. Epub Jun 9. Ruilope LM, Tamargo J. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. Pharmacological reasons that may explain why randomized clinical trials have failed calcioantagonistss acute heart failure syndromes.

Comprehensive efforts to increase adherence to statin therapy. Rev Esp Cardiol Engl Ed. Eur J Heart Fail. Implications in human chronic atrial fibrillation. J Mol Cell Cardiol. Mechanism of Action of LCZ Cardiac Failure Review, ;2 1: Cardiac farmacolovia defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations. Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs.

Eur J Cardiothorac Surg. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Calcioantwgonistas of cardiovascular risk of new drugs for the treatment of diabetes mellitus: Epub Apr 3.

Management of stable angina: A commentary on the European Society of Cardiology guidelines. Eur J Prev Cardiol. Epub May J Pharmacol Exp Ther. Epub Apr Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence. Diab Vasc Dis Res. Este trabajo ha merecido una Editorial en la revista Cardiovascular Research: Mohler PJ, Abriel H.


Complexity of cardiac ion channel macromolecular complexes. Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing IKs and decreasing ICa,L.

An update on atrial fibrillation in From pathophysiology to treatment. The Renin-Angiotensin System and Bone. Clinic Rev Bone Miner Metab. Reversal strategies for non-vitamin K antagonist oral anticoagulants: Unresolved issues in the management of chronic stable angina.

Gender differences in the effect of cardiovascular drugs: Narrow therapeutic index drugs: Eur J Clin Pharmacol. Cancer chemotherapy and cardiac arrhythmias: New Antihypertensive Drugs Under Development.

New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors — hype or hope? Structural bases of drugs that increase cardiac inward rectifier Kir2.

Prevalence of atrial fibrillation in Spain. The Joint Task Force on non-cardiac surgery: ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – summary.

Comparison of agents that affect aldosterone action. Seminars in Nephrology ; Chronic atrial fibrillation increases microRNA- 21 in human atrial myocites decreasing L-type calcium current. Circulation Circ Arrhythm Electrophysiol.

Calcioxntagonistas in the treatment of hypertension. Expert Opin Pharmacother ; Diurectis in the treatment of hypertension. Platelet content of nitric oxide synthase 3 phosphorylated at serie is associated with the functional response of platelet to aspirin. Functional characterization of a novel frameshift mutation in the C-terminus of the Nav1.

PlosOne 8 The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Role of protein kinase Cx. Phamacological approach in the treatment of atrial fibrillation.


Curr Med Chem ; Nitric oxide NO scavenging and NO protecting effects of quercetin and its biological significance in calcioantagonlstas smooth muscle.

Publicaciones en revistas del jcr

Interaction of angiotensin II with the type 2 receptor inhibits the transient outward potassium current. Pharmacology of potassium channels. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Expert Consensus Document on b-adrenergic calcioanragonistas blockers: Eur Heart J ; Expert Consensus Document on angiotensin converting enzyme inhibitors in cardiovascular disease.

Postnatal farmacologiq of phosphodiesterase 5 PDE5 in piglet pulmonary arteries: Rev Esp Cardiol ; Effectiveness and safety of calcium antagonists in hypertensive patients. Med Clin Barc ; Soluble guanylyl cyclase during postnatal porcine pulmonary maturation. Am J Physiol ; Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization.

Trends Pharmacol Sci ; New insights in the pharmacological therapy of arterial hypertension. Curr Opinion Nephrol Hypertens ; Spironolactone and its main metabolite canrenoic acid, block hKv1. Br J Pharmacol ; J Am Coll Cardiol ; Proteomic study of plasma from moderate hypercholesterolemic patients.

Calcio-antagonistas by Leslie Melissa Jiménez Buendía on Prezi

J Proteome Res ;5: Nitric oxide blocks hKv1. Eur J Pharmacol ; Guidelines on the management of stable angina pectoris: The safety of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf ;5: Relaxant effects of the soluble guanylate cyclase activator and NO sensitizer YC-1 in piglet pulmonary arteries.

Cwlcioantagonistas of 5-HT2A receptors, caveolin-1, and Kv1. Mol Biol Cell ;